FULC Q1 2020 Earnings — Fulcrum Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

FULCFulcrum Therapeutics, Inc.

$411M

Q1 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$750,000

Gross Profit

-$14M-1830.9% margin

Operating Income

-$19M-2506.1% margin

Net Income

-$18M-2460.3% margin

EPS (Diluted)

$-0.81

QoQ Revenue Growth

+Infinity%

Cash Flow

Operating Cash Flow

-$15M

Free Cash Flow

-$16M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$95M

Total Liabilities

$24M

Stockholders' Equity

$71M

Cash & Equivalents

$25M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$750,000	$0	—
Gross Profit	-$14M	-$35M	+60.3%
Operating Income	-$19M	-$37M	+49.5%
Net Income	-$18M	-$37M	+49.9%